LAURA MCELROY: Open Payments
NPI 1043210537 · LOUISVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,925 in 76 payments from 15 companies in 2025. Trend: 2023 $2,299 · 2024 $2,123 · 2025 $1,925
Food & beverage: $1,897Consulting: $28
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 8 | $366 |
| AstraZeneca Pharmaceuticals LP | 15 | $300 |
| GlaxoSmithKline, LLC. | 13 | $287 |
| Regeneron Healthcare Solutions, Inc. | 8 | $241 |
| CSL Behring | 10 | $189 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $130 |
| Novartis Pharmaceuticals Corporation | 7 | $119 |
| Amgen Inc. | 4 | $64 |
| Blueprint Medicines Corporation | 1 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
Products named: DUPIXENT, NUCALA, FASENRA, NEFFY, TEZSPIRE, Hizentra, Rhapsido, AYVAKIT.
Industry payments across KY — which companies pay providers there.
